MA53432A - Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk - Google Patents

Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk

Info

Publication number
MA53432A
MA53432A MA053432A MA53432A MA53432A MA 53432 A MA53432 A MA 53432A MA 053432 A MA053432 A MA 053432A MA 53432 A MA53432 A MA 53432A MA 53432 A MA53432 A MA 53432A
Authority
MA
Morocco
Prior art keywords
pyridazines
imidazo
trk inhibitors
trk
inhibitors
Prior art date
Application number
MA053432A
Other languages
English (en)
Inventor
Alan Brown
Angela Glen
Original Assignee
Benevolentai Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevolentai Bio Ltd filed Critical Benevolentai Bio Ltd
Publication of MA53432A publication Critical patent/MA53432A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053432A 2018-08-23 2019-08-23 Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk MA53432A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1813791.9A GB201813791D0 (en) 2018-08-23 2018-08-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA53432A true MA53432A (fr) 2021-06-30

Family

ID=63715095

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053432A MA53432A (fr) 2018-08-23 2019-08-23 Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk

Country Status (21)

Country Link
US (1) US20210253572A1 (fr)
EP (1) EP3840832B1 (fr)
JP (1) JP7417594B2 (fr)
KR (1) KR20210049089A (fr)
CN (1) CN112805062B (fr)
AU (1) AU2019325375A1 (fr)
BR (1) BR112021003026A2 (fr)
CA (1) CA3106431A1 (fr)
DK (1) DK3840832T3 (fr)
EA (1) EA202190323A1 (fr)
ES (1) ES2968695T3 (fr)
FI (1) FI3840832T3 (fr)
GB (1) GB201813791D0 (fr)
HU (1) HUE065655T2 (fr)
IL (1) IL280513B1 (fr)
MA (1) MA53432A (fr)
MX (1) MX2021002051A (fr)
PL (1) PL3840832T3 (fr)
PT (1) PT3840832T (fr)
SG (1) SG11202100338PA (fr)
WO (1) WO2020039209A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021210187A1 (en) * 2020-01-22 2022-07-21 Benevolentai Bio Limited Pharmaceutical compositions and their uses
BR112022013161A2 (pt) * 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
WO2022234287A1 (fr) 2021-05-06 2022-11-10 Benevolentai Bio Limited Dérivés d'imidazopyridazine utiles en tant qu'inhibiteurs de trk
CN113444070A (zh) * 2021-07-28 2021-09-28 深圳市真味生物科技有限公司 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UY33597A (es) * 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN105130967B (zh) 2011-05-13 2018-04-17 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
MX356401B (es) 2011-12-12 2018-05-21 Dr Reddys Laboratories Ltd Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk).
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
WO2014175370A1 (fr) 2013-04-25 2014-10-30 塩野義製薬株式会社 Dérivé de pyrrolidine et composition pharmaceutique en contenant
EA202091475A1 (ru) 2017-12-15 2020-09-09 Пирамид Байосайенсиз, Инк. ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
GB201811825D0 (en) * 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds

Also Published As

Publication number Publication date
KR20210049089A (ko) 2021-05-04
JP7417594B2 (ja) 2024-01-18
CA3106431A1 (fr) 2020-02-27
MX2021002051A (es) 2021-06-23
SG11202100338PA (en) 2021-03-30
IL280513B1 (en) 2024-07-01
HUE065655T2 (hu) 2024-06-28
EA202190323A1 (ru) 2021-05-28
CN112805062B (zh) 2024-06-04
WO2020039209A1 (fr) 2020-02-27
US20210253572A1 (en) 2021-08-19
CN112805062A (zh) 2021-05-14
PL3840832T3 (pl) 2024-03-25
EP3840832A1 (fr) 2021-06-30
PT3840832T (pt) 2024-01-15
IL280513A (en) 2021-03-01
ES2968695T3 (es) 2024-05-13
FI3840832T3 (fi) 2024-01-12
BR112021003026A2 (pt) 2021-05-11
DK3840832T3 (da) 2024-01-15
GB201813791D0 (en) 2018-10-10
AU2019325375A1 (en) 2021-02-04
EP3840832B1 (fr) 2023-10-11
JP2021535125A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
MA53432A (fr) Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA50456A (fr) Formulations d'un inhibiteur de kinase trk macrocyclique
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MA53487A (fr) Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3452481A4 (fr) Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
ES2974964T3 (es) Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina